Abstract | BACKGROUND: METHODS: A retrospective chart review of 42 patients seen by one clinician that met established CVS diagnostic criteria revealed 30 cases with available outcome data. Participants were treated on a loose protocol consisting of fasting avoidance, co-enzyme Q10 and L-carnitine, with the addition of amitriptyline (or cyproheptadine in those < 5 years) in refractory cases. Blood level monitoring of the therapeutic agents featured prominently in management. RESULTS:
Vomiting episodes resolved in 23 cases, and improved by > 75% and > 50% in three and one additional case respectively. Among the three treatment failures, two could not tolerate amitriptyline (as was also the case in the child with only > 50% efficacy) and one had multiple congenital gastrointestinal anomalies. Excluding the latter case, substantial efficacy (> 75% response) was 26/29 at the start of treatment, and 26/26 in those able to tolerate the regiment, including high dosages of amitriptyline. CONCLUSION:
|
Authors | Richard G Boles |
Journal | BMC neurology
(BMC Neurol)
Vol. 11
Pg. 102
(Aug 16 2011)
ISSN: 1471-2377 [Electronic] England |
PMID | 21846334
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic Uptake Inhibitors
- Vitamins
- Ubiquinone
- Amitriptyline
- coenzyme Q10
- Carnitine
|
Topics |
- Adolescent
- Adrenergic Uptake Inhibitors
(therapeutic use)
- Adult
- Amitriptyline
(therapeutic use)
- Carnitine
(therapeutic use)
- Child
- Child, Preschool
- Diet Therapy
- Female
- Humans
- Male
- Retrospective Studies
- Ubiquinone
(analogs & derivatives, therapeutic use)
- Vitamins
(therapeutic use)
- Vomiting
(diet therapy, drug therapy)
- Young Adult
|